FDA Grants Soligenix “Fast Track” Designation for Dusquetide in the Treatment of Oral Lesions of Behçet’s Disease

January 8, 2024

https://www.prnewswire.com/news-releases/fda-grants-soligenix-fast-track-designation-for-dusquetide-in-the-treatment-of-oral-lesions-of-behcets-disease-302026627.html

PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet’s Disease has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA).

Read more at prnewswire.com

Related news for (SNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.